WO2020200256A1 - Protéine de fusion et son utilisation - Google Patents

Protéine de fusion et son utilisation Download PDF

Info

Publication number
WO2020200256A1
WO2020200256A1 PCT/CN2020/082861 CN2020082861W WO2020200256A1 WO 2020200256 A1 WO2020200256 A1 WO 2020200256A1 CN 2020082861 W CN2020082861 W CN 2020082861W WO 2020200256 A1 WO2020200256 A1 WO 2020200256A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
seq
amino acid
cancer
antibody
Prior art date
Application number
PCT/CN2020/082861
Other languages
English (en)
Chinese (zh)
Inventor
吕明
丁晓然
缪仕伟
谈彬
王学恭
Original Assignee
杭州尚健生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州尚健生物技术有限公司 filed Critical 杭州尚健生物技术有限公司
Priority to EP20782966.4A priority Critical patent/EP3950720A4/fr
Priority to CA3131075A priority patent/CA3131075A1/fr
Priority to BR112021019570A priority patent/BR112021019570A2/pt
Priority to JP2021556959A priority patent/JP2022527705A/ja
Priority to SG11202110400QA priority patent/SG11202110400QA/en
Priority to US17/599,733 priority patent/US20220251154A1/en
Priority to CN202080023723.7A priority patent/CN113631582A/zh
Priority to KR1020217030645A priority patent/KR20210146916A/ko
Priority to AU2020250613A priority patent/AU2020250613A1/en
Publication of WO2020200256A1 publication Critical patent/WO2020200256A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une protéine de fusion, et un immunoconjugué, une molécule d'acide nucléique, un véhicule, une composition, une cellule et un procédé de préparation associé, pour le traitement de tumeurs et/ou de maladies auto-immunes.
PCT/CN2020/082861 2019-04-02 2020-04-01 Protéine de fusion et son utilisation WO2020200256A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP20782966.4A EP3950720A4 (fr) 2019-04-02 2020-04-01 Protéine de fusion et son utilisation
CA3131075A CA3131075A1 (fr) 2019-04-02 2020-04-01 Proteine de fusion et son utilisation
BR112021019570A BR112021019570A2 (pt) 2019-04-02 2020-04-01 Proteína de fusão, imunoconjugado, ácido nucleico isolado, vetor, célula, composição, uso dos mesmos para tratar um tumor, bem como métodos para preparar a proteína de fusão, para bloquear a interação entre a proteína pd-l1 e pd-1 e entre cd47 e sirp-alfa e para inibir o crescimento e/ou proliferação de tumores ou células tumorais
JP2021556959A JP2022527705A (ja) 2019-04-02 2020-04-01 融合タンパク質およびその使用
SG11202110400QA SG11202110400QA (en) 2019-04-02 2020-04-01 Fusion protein and use thereof
US17/599,733 US20220251154A1 (en) 2019-04-02 2020-04-01 Fusion protein and use thereof
CN202080023723.7A CN113631582A (zh) 2019-04-02 2020-04-01 一种融合蛋白及其用途
KR1020217030645A KR20210146916A (ko) 2019-04-02 2020-04-01 융합 단백질 및 이의 용도
AU2020250613A AU2020250613A1 (en) 2019-04-02 2020-04-01 Fusion protein and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910260447.5 2019-04-02
CN201910260447.5A CN111763261B (zh) 2019-04-02 2019-04-02 一种融合蛋白及其用途

Publications (1)

Publication Number Publication Date
WO2020200256A1 true WO2020200256A1 (fr) 2020-10-08

Family

ID=72664537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/082861 WO2020200256A1 (fr) 2019-04-02 2020-04-01 Protéine de fusion et son utilisation

Country Status (10)

Country Link
US (1) US20220251154A1 (fr)
EP (1) EP3950720A4 (fr)
JP (1) JP2022527705A (fr)
KR (1) KR20210146916A (fr)
CN (2) CN111763261B (fr)
AU (1) AU2020250613A1 (fr)
BR (1) BR112021019570A2 (fr)
CA (1) CA3131075A1 (fr)
SG (1) SG11202110400QA (fr)
WO (1) WO2020200256A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022177394A1 (fr) * 2021-02-19 2022-08-25 (주)샤페론 Anticorps bispécifique à domaine unique dirigé contre pd-l1 et cd47 et son utilisation
WO2023072279A1 (fr) * 2021-11-01 2023-05-04 江苏先声药业有限公司 Sirpa mutant et son application

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113773401B (zh) * 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
CN116178561A (zh) * 2021-11-26 2023-05-30 杭州尚健生物技术有限公司 包含SIRPα突变体的融合蛋白

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5436327A (en) 1988-09-21 1995-07-25 Isis Innovation Limited Support-bound oligonucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
CN103608684A (zh) * 2011-05-12 2014-02-26 基因泰克公司 利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
CN107459578A (zh) * 2016-05-31 2017-12-12 泰州迈博太科药业有限公司 一种靶向cd47与pd‑l1的双功能融合蛋白
CN109535263A (zh) * 2018-12-04 2019-03-29 江苏东抗生物医药科技有限公司 SIRPα突变体及其融合蛋白

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848929A (zh) * 2007-05-25 2010-09-29 诺华有限公司 肺炎链球菌菌毛抗原
CN106535914B (zh) * 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-α变体构建体及其用途
CA2957531A1 (fr) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Proteines de fusion sirp alpha-anticorps
CN107108748A (zh) * 2014-08-15 2017-08-29 默克专利有限公司 SIRPα免疫球蛋白融合蛋白
RU2740672C2 (ru) * 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
EP3331901A1 (fr) * 2015-08-07 2018-06-13 Pieris Pharmaceuticals GmbH Nouveau polypeptide de fusion spécifique de lag-3 et pd-1
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CA3044684A1 (fr) * 2016-12-09 2018-06-14 Alector Llc Anticorps anti-sirp-alpha et leurs procedes d'utilisation
WO2018205936A1 (fr) * 2017-05-08 2018-11-15 上海津曼特生物科技有限公司 Protéine recombinante bispécifique et son utilisation
CN109517054B (zh) * 2018-12-04 2022-04-08 江苏东抗生物医药科技有限公司 SIRPα变体或其融合蛋白及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5436327A (en) 1988-09-21 1995-07-25 Isis Innovation Limited Support-bound oligonucleotides
CN103608684A (zh) * 2011-05-12 2014-02-26 基因泰克公司 利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
CN107459578A (zh) * 2016-05-31 2017-12-12 泰州迈博太科药业有限公司 一种靶向cd47与pd‑l1的双功能融合蛋白
CN109535263A (zh) * 2018-12-04 2019-03-29 江苏东抗生物医药科技有限公司 SIRPα突变体及其融合蛋白

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. 29126
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO.
ALTSCHULW. GISHW. MILLERE. W. MYERSD. LIPMAN, JOURNAL OF MOLECULAR BIOLOGY, vol. 215, 1990, pages 403 - 410
AUSUBEL, F. M. ET AL.: "Current Protocols in Molecular Biology", 1987, GREENE PUBLISHING ASSOC. AND WILEY-INTERSCIENCE
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CO ET AL., J IMMUNOL, vol. 148, 1992, pages 1149 - 1154
CO ET AL., PROC NATL ACAD SCI USA, vol. 88, 1991, pages 2869 - 2873
D. J. LIPMANW. R. PEARSON, SCIENCE, vol. 227, 1989, pages 1435 - 1441
JONES ET AL., NATURE, vol. 321, 1986, pages 522
LEE, H.T. ET AL.: "Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab", SCIENTIFIC REPORTS, 17 July 2017 (2017-07-17), XP055454737, DOI: 20200530175311Y *
MARK ET AL.: "Cellular adhesion: molecular definition to therapeutic potential", 1994, PLENUM PRESS, article "Derivation of therapeutically active humanized and veneered anti-CD18 antibodies", pages: 291 - 312
MARKS ET AL., MOL. BIOL., vol. 222, 1991, pages 581 - 597
MATTEUCI ET AL., TET. LETT., vol. 521, 1980, pages 719
QUEEN ET AL., PROC NATL ACAD SCI USA, vol. 86, 1989, pages 10029 - 10033
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 337
SAMBROOK, J.FRITSCH, E. F.MANIATIS, T.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
See also references of EP3950720A4
T. J. SILHAVYM. L. BENNANL. W. ENQUIST: "Experiments with Gene Fusions", 1984, COLD SPRING HARBOR LABORATORY
TEMPEST ET AL., BIO/TECHNOL, vol. 9, 1991, pages 266 - 271
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
W. R. PEARSOND. J. LIPMAN, PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 2444 - 2448
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022177394A1 (fr) * 2021-02-19 2022-08-25 (주)샤페론 Anticorps bispécifique à domaine unique dirigé contre pd-l1 et cd47 et son utilisation
WO2023072279A1 (fr) * 2021-11-01 2023-05-04 江苏先声药业有限公司 Sirpa mutant et son application

Also Published As

Publication number Publication date
EP3950720A1 (fr) 2022-02-09
CN111763261A (zh) 2020-10-13
JP2022527705A (ja) 2022-06-03
SG11202110400QA (en) 2021-10-28
CN113631582A (zh) 2021-11-09
BR112021019570A2 (pt) 2021-11-30
CA3131075A1 (fr) 2020-10-08
AU2020250613A1 (en) 2021-11-11
US20220251154A1 (en) 2022-08-11
EP3950720A4 (fr) 2023-04-12
KR20210146916A (ko) 2021-12-06
CN111763261B (zh) 2022-08-09

Similar Documents

Publication Publication Date Title
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
WO2020200256A1 (fr) Protéine de fusion et son utilisation
WO2018036472A1 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
WO2017071625A1 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
WO2021227940A1 (fr) Anticorps anti-tigit, son procédé de préparation et son utilisation
WO2020098672A1 (fr) Protéine de fusion et son utilisation
WO2023093831A1 (fr) Protéine de fusion comprenant un mutant sirp-alpha
CN112661855B (zh) 含SIRPa变体的融合蛋白
US20230227572A1 (en) Anti-pvrig protein antibody or antibody fragment and use thereof
TW202144412A (zh) 一種融合蛋白及其用途
WO2023241629A1 (fr) Anticorps anti-cldn18.2, composition pharmaceutique et utilisation associées
WO2022199527A1 (fr) Protéine de liaison à l'antigène ciblant la protéine hémolysine de streptococcus pneumoniae et son utilisation
KR20230022334A (ko) Api5에 특이적으로 결합하는 항체 및 이의 용도
CN116724057A (zh) 蛋白酶可切割的重组双特异性抗体和组合物及其用途
CN115521378A (zh) Pd-l1抗体及其用途
CN117736330A (zh) 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20782966

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3131075

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021556959

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021019570

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020250613

Country of ref document: AU

Date of ref document: 20200401

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020782966

Country of ref document: EP

Effective date: 20211102

ENP Entry into the national phase

Ref document number: 112021019570

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210929